# RevolKa

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/revolka

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.revolka.com
- Total disclosed funding: $4.9M
- Latest round: Series A (May 19, 2025)
- Investors on record: 4

## About

Founded in 2021 and based in Tokyo, Japan, Revolka Ltd. operates as a biotechnology research company that develops biopharmaceuticals using its proprietary artificial intelligence-based protein engineering technology. In August 2024, Deepcore and D3 LLC co-led a JPY 100 million Series A funding for RevolKa Ltd.

RevolKa specializes in protein engineering, utilizing its proprietary aiProtein® technology, which combines artificial intelligence with directed protein evolution. This technology accelerates the creation of engineered proteins and enables multi-dimensional modifications to enhance various properties, including efficacy and manufacturability of therapeutic antibodies. RevolKa is open to research collaborations and co-development opportunities related to its internal projects.

The company intends to use the August 2024 funding to accelerate its drug discovery and development activities.

## Funding rounds

- Series A, May 19, 2025, $1.4M — TOHOKU University Venture Partners, Deepcore, D3 LLC
- Series A, Aug 29, 2024, $0.7M — Deepcore, D3 LLC
- Series A, May 31, 2022, $2.8M — SBI Investment, TOHOKU University Venture Partners

## Investors

- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series A
- TOHOKU University Venture Partners (https://capitalatlas.ai/funds/tohoku-university-venture-partners) — Series A
- Deepcore (https://capitalatlas.ai/funds/deepcore) — Series A
- D3 LLC (https://capitalatlas.ai/funds/d3-llc) — Series A